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ABSTRACT: Dextrin−colistin conjugates have been devel-
oped with the aim of achieving reduced clinical toxicity
associated with colistin, also known as polymyxin E, and
improved targeting to sites of bacterial infection. This study
investigated the in vitro ability of such dextrin−colistin
conjugates to bind and modulate bacterial lipopolysaccharide
(LPS), and how this binding aﬀects its biological activity.
These results showed that colistin and amylase-activated
dextrin−colistin conjugate to a lesser extent induced
aggregation of LPS to form a stacked bilayer structure with
characteristic dimensions, although this did not cause any
substantial change in its secondary structure. In biological
studies, both colistin and dextrin−colistin conjugate eﬀectively inhibited LPS-induced hemolysis and tumor necrosis factor α
(TNFα) secretion in a concentration-dependent manner, but only dextrin−colistin conjugate showed no additive toxicity at
higher concentrations. This study provides the ﬁrst direct structural experimental evidence for the binding of dextrin−colistin
conjugates and LPS and gives insight into the mode of action of dextrin−colistin conjugates.
■ INTRODUCTION
Infectious diseases account for millions of deaths worldwide
annually with high associated costs.1 Antibiotic chemotherapy is
successfully used to treat the majority of Gram-negative
infections, but antibiotic-induced shedding of endotoxic lip-
opolysaccharides (LPSs) may result in systemic sepsis, with an
associated mortality of 30−50%. Thus, eradication of bacterial
infection does not always lead to a positive clinical outcome. We
have previously described the ﬁrst bioresponsive polymer
conjugates to target the delivery of antimicrobials to sites of
inﬂammation, using dextrin−colistin conjugates as a prototypical
model.2 Colistin (also known as polymyxin E) is an eﬀective
amphiphilic antibiotic that binds to Gram-negative bacterial cell
membranes, resulting in cytoplasmic leakage and cell death. In
clinical use, however, colistin may be associated with
considerable nephro- and neurotoxicity in immunocomprom-
ized patients, which limits its clinical use. These nanoantibiotic
polymer therapeutics are administered centrally but are locally
activated at sites of infection by amylase, an enzyme found
throughout the body (typical serum concentration 60−120 IU/
L) but present at elevated concentrations at sites of infection or
inﬂammation.3 This local activation improves antibiotic targeting
to sites of infection, enables the unmasking and localized release
of free colistin (using polymer masked−unmasked protein
therapy (PUMPT)),4 and reduces clinical toxicity.
An important property of colistin is its ability to bind bacterial
LPS and block its toxic biological activities5 (Figure 1). The
phase structure, conformation, and aggregation behavior of
bacterial LPS and its components (e.g., lipid A) have been
extensively characterized by various physical methods.6−8 LPS is
biologically active in its micellar form, and colistin disaggregation
eﬀectively neutralizes its endotoxic eﬀects by disrupting the
regular spacing of LPS fatty acid chains and binding in a 1:1
complex.9 While the toxicity proﬁle and antibacterial activity of
the dextrin−colistin conjugates have been described, its potential
structural and functional interactions with LPS are unknown. In
these studies, colistin−LPS complex formation and potential
LPS neutralization was studied using small-angle neutron
scattering (SANS), circular dichroism (CD) spectroscopy, and
turbidity assays to characterize the in vitro ability of the
conjugates to bind and modulate bacterial LPS from Escherichia
coli and determine how the degree of unmasking aﬀected LPS
binding. Parallel studies investigated in vitro inhibition of LPS-
induced erythrocyte hemolysis and tumor necrosis factor α
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(TNFα) release from human kidney (HK-2) cells as a marker of
LPS complex formation with colistin sulfate, colistimethate
sodium (CMS), and dextrin−colistin conjugate.
■ RESULTS
Endotoxin Binding. In SANS experiments, LPS aggregates
showed signiﬁcant scattering intensity, I(Q) as a function of the
wavevector, Q. This scattering is characteristic of the size, shape,
and distribution of the scattering centers within the system under
investigation. Clearly, the pattern was altered in the presence of
colistin or unmasked dextrin−colistin conjugate at ≥10 mg/mL
(Figure 2). The emergence of two peaks atQ = 0.06 and 0.11 Å−1
and a pronounced increase in scattering intensity at low Q was
apparent when LPS was combined with colistin. These peaks did
not change position with diﬀerent colistin concentrations,
although the intensity of the peaks varied and was greatest
with 10 mg/mL colistin. When LPS was preincubated with
dextrin−colistin conjugate, the intensity decreased at low Q.
Preincubation of dextrin−colistin conjugate with amylase,
however, induced a time-dependent increase in scattering
intensity at low Q and the appearance of a peak at Q = 0.06
Å−1. Clearly the peaks are a result of the action of the colistin on
the LPS structure.
When aggregation or association is induced in a sample at
constant weight concentration, the scattering intensity reﬂects
the changing distribution of scatterers within the system and, as
such, is a complex interplay between the size and shape of the
aggregated form
= +I Q n V P Q S Q B( ) ( ) ( )p p2 inc
where np is the number concentration of the scatterers, Vp is their
volume, and P(Q) and S(Q) are mathematical functions that
describe their shape and distribution. Hence, for a ﬁxed mass
concentration, aggregation leads to a decrease in np but an
increase in Vp, as well as changes in P(Q) and S(Q). Here, the
scattering is dominated by the LPSs, such that at low Q values, a
shape-independent P(Q) approach may be invoked (P(Q)→ 1,
S(Q) → 1), where I(Q) ∝ exp[(QRg)2/3]. Hence, a plot of ln
I(Q) vs Q2 (a Guinier plot) will be linear, with slope Rg
2/3; a
steep slope indicates a large size. An example of a Guinier plot is
presented in the Supporting Information, and the Rg values are
presented in Figure 2c. Rg is greatest for the LPS with colistin
sulfate structure and smallest for the structure formed by LPSs in
the presence of the masked dextrin−colistin conjugate.
Interestingly, the structure of LPSs with masked dextrin−colistin
conjugate is smaller than that of LPSs only, indicating that the
masked conjugate must disrupt the LPS structure somewhat.
Upon addition of colistin sulfate at 10 mg/mL, aggregation is
induced leading to larger structures (steeper decay) and the
emergence of the peaks indicating a stacked structure with
characteristic dimensions L = 50 Å, with the second peak arising
due to the second order reﬂection. The unmasked conjugate was
seen to have little eﬀect on the LPS structure. At the higher
colistin concentration (50 mg/mL), the perturbation induced by
the colistin is much greater with the signature of the stacked
layers also emerging with the unmasked conjugates. At both
conjugate concentrations, there is a downturn at low Q,
indicating slightly smaller structures.
CD spectra recorded from 260 to ∼180 nm mainly reﬂect the
conformation of the colistin peptide bonds (Figure 3a−c). The
pronounced minimum at 198 nm is indicative of a random coil
conformation though the shoulder in the 215−225 nm range
reﬂects some ordered structures. Neither conjugation with
dextrin (Figure 3b) nor subsequent unmasking by amylase
(Figure 3c) showed any eﬀect on the peptide conformation.
Succinoylated dextrin showed no CD signal within the accessible
wavelength range (data not shown). When LPS was added to the
antibiotic solutions, the CD spectra appeared to be equivalent to
the sum of the CD signals of the individual components.
Increasing turbidity was used as a marker of LPS aggregate
formation with colistin, CMS, or dextrin−colistin conjugate.
When compared at equivalent colistin concentration, signiﬁcant
diﬀerences between the turbidity of colistin and CMS, dextrin−
colistin (with or without amylase), or control were observed
(Figure 3d). LPS binding of the dextrin−colistin conjugate was
reduced to∼50% compared with free colistin; turbidity remained
unaltered even after preincubation of the conjugate with amylase.
Colistin and CMS to a lesser extent were able to inhibit the
cleavage of chromogenic substrate by LPSs (Figure 4).
Neutralization of LPS by colistin required 20-fold more LPSs
to trigger Limulus amebocyte lysate (LAL) gelation compared
with LPSs in water and was signiﬁcantly greater than that with
CMS (1 vs 0.05 ng/mL, respectively). All dextrin−colistin
conjugate samples gelled Limulus amebocyte lysate without the
addition of LPSs. Nevertheless, at the lower concentrations of
LPSs, unmasked conjugate was capable of binding more LPSs
than masked conjugate, and there was a trend for increasing
endotoxin binding after unmasking by amylase (6 h > 24 h > 0 h)
(data not shown).
In Vitro Inhibition of Endotoxin Activity. When HK-2
cells were treated with LPSs alone or in the presence of colistin
sulfate, CMS, or unmasked dextrin−colistin conjugate, there was
little eﬀect on LPS-induced TNFα release at low concentrations,
but increased cytokine release was observed when colistin molar
concentration exceeded that of LPSs (Figure 5). However, at
both LPS concentrations (10 and 100 ng/mL), dextrin−colistin
conjugate inhibited LPS-induced TNFα release in a concen-
tration-dependent manner above 5 and 50 μg/mL, respectively.
Similarly, addition of colistin sulfate, CMS, and dextrin−
colistin conjugate inhibited endotoxin-induced hemolysis of rat
erythrocytes up to ∼20 μg/mL (Figure 6). However, while
higher concentrations of colistin and CMS caused increasing
erythrocyte lysis, dextrin−colistin conjugate continued to inhibit
hemolysis in a concentration-dependent manner. Unmasked
dextrin−colistin conjugate was unable to inhibit endotoxin-
Figure 1. Representation of the antiendotoxin mechanism of dextrin−
colistin conjugate, showing the unmasking strategy utilized to control
delivery of colistin and the eﬀect of colistin on LPS aggregates.
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induced hemolysis and caused equivalent toxicity to colistin and
CMS at higher concentrations.
■ DISCUSSION
A detailed understanding of the physicochemical properties and
structure−activity relationships is vital to predict the behavior of
polymer therapeutics in biological systems and ensure the design
of safe and eﬃcacious nanomedicines. The ability of colistin to
bind and neutralize LPS is well documented; however little is
known about how polymer conjugation aﬀects the structural and
biological properties of colistin. While the antimicrobial activity
of dextrin−colistin conjugates has been demonstrated in vitro,2
antibiotic treatment may induce LPS release from lysed bacteria,
which may trigger the immune system to induce endotoxic
shock. Therefore, these studies investigated whether dextrin−
colistin conjugates (before and after amylase “unmasking”) could
Figure 2. Small-angle neutron scattering from LPS (10 mg/mL in D2O) following incubation (3 h at 37 °C) with colistin sulfate, dextrin−colistin
conjugate, and unmasked dextrin−colistin conjugates at (a) 10 and (b) 50 mg/mL. Panel c shows the radii of gyration (Rg) calculated from the SANS
data.
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bind and neutralize released endotoxins. Dextrin−colistin
conjugates used in these studies contained ∼10% w/w colistin,
of which <2% was unbound, indicating multiple (typically two)
dextrin chains per colistin with several (typically three) binding
sites. The dextrin−colistin concentrations used in the SANS and
CD spectroscopy studies refer to total conjugate; thus conjugate
samples contained ∼10× less colistin than the equivalent free
drug samples. While this may aﬀect the biological activity of the
conjugates, it was deemed the most appropriate means of
comparing the samples in these structural studies.
The use of SANS to study evolving biological systems has been
previously employed to investigate dextrin−phospholipase A2-
triggered degradation of liposomes.10 Here, we examined the
eﬀect of dextrin conjugation and unmasking by amylase on the
interaction of colistin with LPSs. With a critical micelle
concentration of ∼14 μg/mL,8,11 LPSs readily micellize at the
concentrations used in these studies. These studies assumed, not
unreasonably, that the SANS scattering is dominated by that of
the LPSs. The data revealed signiﬁcant conformational
rearrangement of LPSs following incubation with both colistin
sulfate and unmasked dextrin−colistin conjugate (colistin sulfate
> 24 h unmasked dextrin−colistin > 6 h unmasked dextrin−
colistin) at≥10mg/mL. This conformational rearrangement was
evident in the emergence of the peaks indicative of a regular
ordered structure.
Similarly, marked diﬀerences between the aggregation of
colistin and LPSs and that observed with dextrin−colistin
conjugates were evident in both the turbidity and LAL assays.
The CD spectra of colistin sulfate were in agreement with the
solution structure derived by nuclear magnetic resonance
(NMR) spectroscopy,9 showing overall high mobility but some
β-turn formed by residues 5−8. However, CD spectroscopy did
not show any substantial change in the secondary structure of
colistin or dextrin−colistin conjugates (masked and unmasked)
in the presence of LPS, indicating that this aggregation did not
induce an α-helical structure, presumably due to the rigidity of
colistin’s cyclic structure. This has also been observed with
polymyxin B, while WLBU2, a cationic amphiphilic peptide,
became markedly helical in the presence of LPSs, a ﬁnding
attributed to the ability of polymyxin B (but not WLBU2) to
destabilize and disrupt LPS vesicles.12
Molecular modeling has demonstrated that colistin exerts its
antiendotoxic eﬀects by breaking up the supramolecular
structure of LPSs.9 The downturn in the SANS from LPSs at
low Q in the presence of colistin (50 mg/mL) is an indication of
this neutralization eﬀect, since LPSs and colistin have been
shown to bind at a LPS to colistin ratio of 5.2:1 (by weight).13
Figure 3.CD spectra of (a) colistin sulfate, (b) dextrin−colistin conjugate, and (c) unmasked dextrin−colistin conjugate (0.5 mg/mL) in 100 mMNaF,
20 mM KH2PO4, pH 7.4, and following incubation (3 h at 37 °C) with LPS (0.1 mg/mL), where sum = LPS signal + colistin signal and dif = LPS−
colistin mixture signal− sum. Panel d shows precipitation of LPS from E. coli (1 mg/mL) in the absence and presence of colistin sulfate, CMS, dextrin−
colistin conjugate, and unmasked dextrin−colistin conjugate (4 mg/mL colistin equiv). Data represent mean ± SEM, n = 6; *p < 0.01 and **p < 0.001
indicate signiﬁcance compared with LPS alone (control).
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The regularity and clarity of the peaks in the SANS induced by
colistin are commensurate with a spacing of 5 nm, suggestive of a
bilayer stack. The 5 nm structures seen here are in good
agreement with the reported size of the lipid A bilayer
component of bacterial LPS, described in both SANS6 and
molecular modeling and X-ray powder diﬀraction experiments.14
These studies demonstrated that lipid A and rough LPS (having a
short O-speciﬁc chain, like E. coliO26:B6 used here) are 2.4 and
2.8 nm long, respectively. This would indicate that the structures
seen in these studies are from the LPSs. This is further supported
by Wallace et al.,15 who reported that colistin aggregates formed
above 2.1 μg/mL with a diameter of 2.07 ± 0.3 nm.
Binding and structural data using several biophysical
techniques, including isothermal titration calorimetry, ﬂuores-
cent probes, and NMR spectroscopy, have indicated that the
LPS−colistin interaction is a two-stage mechanism.16 First, the
complex is stabilized by electrostatic charges between colistin’s
positive charges and LPS’s negatively charged head groups.
Subsequently, complexation is strengthened by hydrophobic
interactions between the hydrophobic domains of the two
molecules. Given that dextrin−colistin conjugation uses
approximately three of colistin’s positively charged amine groups,
it is unsurprising that masked conjugates have no eﬀect on LPS
structure. While unmasked conjugates induced some conforma-
tional rearrangement of LPS, this was not as obvious as with
native colistin. This was not surprising since α-amylase is an
endoamylase that cleaves dextrin within the polyglucose chain;
thus, unmasked dextrin−colistin conjugates retain oligosacchar-
ide fragments attached to colistin’s amine groups, which would
reduce its cationic charge.
Parallel studies investigated in vitro inhibition of LPS-induced
erythrocyte lysis and TNFα release from human kidney cells as a
marker of LPS aggregate formation with colistin or dextrin−
colistin conjugate. Following systemic administration, dextrin−
colistin conjugates are expected to remain in the bloodstream for
an extended period, due to their macromolecular size, but would
ultimately be excreted via the kidneys following amylase
unmasking. Despite the negligible binding to bacterial LPS, the
ability of dextrin−colistin conjugates to exert a protective eﬀect
from endotoxins on erythrocytes and human kidney cells was in
keeping with previous studies showing that dextrin is able to
eﬀectively impede the hemolytic activity of drugs, such as
zidovudine,17 and proteins, such as phospholipase A2.
18 In these
previous studies, the eﬀect was evident when zidovudine was
covalently linked to dextrin or physically mixed with dextrin,
providing further proof that dextrin acts by a cytoprotective
mechanism. Moreover, iodine−lithium−α-dextrin conjugates
have been described with antiendotoxin activity.19,20 These
studies demonstrated that iodine−lithium−α-dextrin suppresses
CD14 receptor expression, inhibits LPS-induced pro-inﬂamma-
tory activation of monocytes and neutrophils, and increases
tolerance to endotoxins.
Polymyxin B−dextran 70 conjugates have been described that
eﬀectively inhibit LPS-induced TNFα production in vivo. Lake et
al.21 proposed that polymyxin B−dextran 70 conjugates
neutralize the pathogenic pharmacophore of endotoxin, citing
unpublished studies corroborating its ability to bind to
radiolabeled endotoxin. Interestingly, parallel studies reported
markedly reduced antibiotic activity of dextran−polymyxin B
Figure 4. Colorimetric detection of endotoxin following incubation of
LAL with LPS from E. coli (0−50 ng/mL) in pyrogen-free water or
preincubated for 3 h at 37 °Cwith colistin sulfate, CMS, dextrin−colistin
conjugate, and unmasked dextrin−colistin conjugate (4 μg/mL colistin
equiv). Data represent the mean ± SEM, n = 6; *p < 0.01 and **p <
0.001 indicate signiﬁcance compared with LPS alone (control); ++ (p >
0.001) indicates signiﬁcance compared with dextrin−colistin conjugate.
Figure 5. Inhibition of LPS-induced TNFα release from HK-2 cells
following incubation with colistin sulfate, CMS, dextrin−colistin
conjugate, and dextrin−colistin + amylase at 0.1−1000 μg/mL colistin
equiv (24 h incubation). Panels a and b show cell response to 10 and 100
ng/mL LPS, respectively. Data represents mean percentage TNFα
release ± SD, n = 3; *p < 0.05, **p < 0.01, ***p < 0.001, and ****p <
0.0001 indicate signiﬁcance compared with LPS alone (control).
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conjugates containing 70 000 g/mol dextran and 3.8% w/w
polymyxin B (equivalent to 2.1 polymyxin B per dextran).22 In
contrast, our dextrin−colistin conjugates contain 8000 g/mol
dextrin and 10.1% w/w colistin, equivalent to 1.6 dextrin chains
per colistin, which may explain the diﬀerence in antibacterial
activity.
■ CONCLUSIONS
These data demonstrate physical diﬀerences in the LPS
interaction of colistin and dextrin−colistin conjugates pre- and
postamylase unmasking. No change in the LPS structure was
observed for dextrin−colistin conjugates; however, degradation
of conjugates showed time-dependent changes in LPS complex
formation that were more pronounced after prolonged
incubation with amylase. Despite the inability of dextrin−colistin
conjugates to bind to bacterial LPS, concentration-dependent
inhibition of LPS-induced toxicity was evident, indicating that
dextrin−colistin conjugates could represent eﬀective neutralizers
of endotoxin with application in the treatment of sepsis.
■ EXPERIMENTAL SECTION
Dextrin−Colistin Conjugate Synthesis and Unmasking.
Dextrin−colistin conjugate was synthesized, using 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride and N-hydroxysul-
fosuccinimide and characterized as previously described.2 The dextrin−
colistin conjugate used in these studies contained dextrin with 1.1 mol %
succinoylation and had a molecular weight of approximately 9000 g/mol
(gel permeation chromatography with pullulan standards) and a colistin
content of approximately 10.1% w/w (by bicinchoninic acid assay) with
<3% free colistin (by fast protein liquid chromatography). Purity of
dextrin−colistin conjugates was ≥95% (by gel permeation chromatog-
raphy). If not stated otherwise, unmasked dextrin−colistin conjugates
were prepared by incubation of dextrin−colistin conjugate (10 mg/mL)
with amylase (100 IU/L) for 24 h at 37 °C.
Small-Angle Neutron Scattering Measurements. To assess the
colistin-induced disruption of LPS aggregates, LPS from E. coli 026:B6
(5) (10 mg/mL; Sigma-Aldrich, U.K.) was incubated with succinoylated
dextrin, colistin sulfate (Sigma-Aldrich, U.K.), dextrin−colistin
conjugate, or unmasked dextrin−colistin conjugate (0.01, 0.1, 1, 10,
or 50 mg/mL) in deuterium oxide (D2O) (Sigma-Aldrich, U.K.)
containing phosphate buﬀered saline (PBS, 137mMNaCl, 3 mMKCl, 8
mM Na2HPO4, 1.5 mM KH2PO4, pH 7.3 (Oxoid, U.K.), 3 h at 37 °C,
pH 7.4) prior to analysis by SANS. Unmasked dextrin−colistin
conjugates were prepared by incubation of dextrin−colistin conjugate
(50 mg/mL in PBS) with α-amylase from human saliva (100 IU/L)
(Sigma-Aldrich, U.K.) for 6 or 24 h at 37 °C, then lyophilized and stored
at −20 °C before reconstitution in D2O prior to analysis by SANS.
SANS experiments were performed on the steady-state reactor source
on the D22 diﬀractometer at the ILL, Grenoble. A Q = (4π/λ)sin(θ/2)
range between 0.005 and 0.5 Å−1 was obtained by choosing two
instrument settings at a constant neutron wavelength (λ) of 6 Å, the two
sample−detector distances were 2 and 14 m, respectively, both working
with the detector being oﬀset by 40 cm with respect to the direct beam
position on the detector. The samples were contained in 2 mm path
length, UV-spectrophotometer grade, quartz cuvettes (Hellma, U.K.).
All experiments were conducted at 37 °C.
All scattering data were (a) normalized for the sample transmission,
(b) background corrected using a quartz cell ﬁlled with PBS in D2O, and
(c) corrected for the linearity and eﬃciency of the detector response
using the instrument speciﬁc software package. Data was analyzed using
SasView 2.2.0 software.
Circular Dichroism Spectroscopy.CD spectra were acquired on a
model 215 spectrometer (AVIV Instrument Inc., Lakewood, NJ) with a
1 mm path length quartz cell at 4 °C. Spectra were recorded at 0.2 nm
intervals with 3 s/point at a 1 nm bandwidth with the dynode voltage <
500 V, and buﬀer baselines were subtracted. Samples were dissolved in
100 mM NaF, 20 mM KH2PO4/NaOH, pH 7.4. Spectra of
succinoylated dextrin, colistin sulfate, dextrin−colistin conjugate, or
unmasked dextrin−colistin conjugate (0.5 mg/mL) were obtained alone
and following incubation with LPS (0.1 mg/mL; 3 h at 37 °C).
Experiments were performed once.
Turbidity Assay. A turbidimetric assay technique was used in which
the binding of LPS to colistin results in precipitation of aggregates and
increased turbidity. LPS was dissolved in prewarmed PBS (1 mg/mL, 37
°C, pH 7.4) containing colistin sulfate, CMS (Colomycin injection,
Forest Laboratories UK Limited, U.K.), dextrin−colistin conjugate, or
unmasked dextrin−colistin conjugate (4 mg/mL colistin equiv, 200 μL
per well) and added to the wells of a 96-well microtiter plate. Control
samples contained only LPS dissolved in PBS. Plates were incubated at
37 °C throughout the experiment, and absorbance was read at 625 nm at
various time points. Samples were assayed in triplicate and experiments
were repeated once.
Limulus Amebocyte Lysate (LAL) Assay. Endotoxin neutraliza-
tion was evaluated using a ToxinSensor chromogenic LAL endotoxin
assay kit (GenScript, U.S.A.). LPS was dissolved in pyrogen free water
(0−50 ng/mL) containing colistin sulfate, CMS, dextrin−colistin
conjugate, or unmasked dextrin−colistin conjugate (4 μg/mL colistin
equiv, 100 μL) in pyrogen-free vials. Control samples contained only
LPS dissolved in pyrogen-free water. Solutions were mixed well and
incubated at 37 °C for 3 h. The manufacturers’ test procedure for
quantitative detection of endotoxins was then followed. The
concentration of LPS producing 50% maximal absorption was taken
as the ED50. Experiments were performed once with six repeated
measures for each concentration.
Unmasked dextrin−colistin conjugates were prepared by incubation
of dextrin−colistin conjugate (0.5 mg/mL in pyrogen free water) with
amylase from human saliva (100 IU/L) for 6 h at 37 °C. The LAL assay
was then followed as described above.
Cell Culture. An immortalized proximal tubule epithelial cell line
from normal human kidney (HK-2, ATCC CRL-2190) was cultured in
keratinocyte-serum free medium (K-SFM) (Invitrogen Life Technol-
ogies, U.K.).
Expression of TNFα. HK-2 cells were seeded into sterile 96-well
microtiter plates (2 × 105 cells/mL) in 0.1 mL/well media and allowed
Figure 6. Inhibition of LPS-induced (100 μg/mL) hemolysis (24 h
incubation) of rat erythrocytes following preincubation with colistin
sulfate, CMS, dextrin−colistin conjugate, and unmasked dextrin−
colistin conjugate for 3 h at 37 °C. Data represents mean ± SEM, n = 9;
*p < 0.05 and **p < 0.001 indicate signiﬁcance compared with LPS
alone (control).
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to adhere for 24 h. Themediumwas then removed and LPS (10 ng/mL)
was added in the absence or presence of colistin sulfate, CMS, or
dextrin−colistin conjugate (with or without amylase, 100 IU/L; 0.2 μm
ﬁlter-sterilized) at diﬀerent concentrations. After 24 h, microtiter plates
were centrifuged (600g, 10 min), and the supernatant was transferred to
a clean 96-well plate and stored at−20 °C until determination of TNFα
content using a commercial human TNFα ELISA set (Thermo
Scientiﬁc, U.K.) according to the manufacturer’s protocol. Absorbance
was measured at 450 nm using a microtiter plate reader. The absorbance
values were expressed as mean± SD (n = 3) and used to calculate TNFα
concentration in pg/mL (assay detection range 15−1000 pg/mL). All
experiments were performed three times for each concentration.
Erythrocyte Lysis. A rat erythrocyte suspension were prepared as
previously described18 and was added to a preincubated (3 h, 37 °C) 96-
well plate containing LPS (100 μg/mL ﬁnal concentration) in the
presence of colistin sulfate, CMS, dextrin−colistin conjugate, or
unmasked dextrin−colistin conjugate (0−500 μg/mL colistin equiv
ﬁnal concentration, 200 μL ﬁnal well volume). PBS was used as a
negative control, and Triton X-100 (1% v/v; Sigma-Aldrich, U.K.) was
used to achieve 100% hemolysis. The plate was incubated for 24 h at 37
°C and then centrifuged at 1500g for 10 min at 4 °C. The supernatant
(100 μL) of each well was then carefully removed and placed into a clean
96-well plate, and absorbance at 540 nm was read. The background
hemolysis (PBS) was subtracted, and the results were expressed as
percentage hemoglobin released (±SEM). Unmasked dextrin−colistin
conjugates were prepared by incubation of dextrin−colistin conjugate (2
mg/mL in PBS) with amylase (100 IU/L) for 24 h at 37 °C. All
experiments were replicated three times with triplicate repeated
measures within each replication for each concentration.
Statistics. The signiﬁcance of the data was assessed using one-way
analysis of variance followed by Bonferroni’s post hoc test. Statistical
signiﬁcance was set at p < 0.05.
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